Merck Downgraded to “Neutral” at Goldman Sachs (MRK)

Comment

Shutterstock photo

Pharma giant Merck & Co., Inc. ( MRK ) saw its rating cut on Wednesday by analysts at Goldman Sachs.

The firm downgraded MRK to "Neutral" from "Buy," and removed the stock from its prestigious "Conviction Buy" List. Goldman noted that the company lacks meaningful near-term catalysts, but maintained its $42 price target on the stock.

Merck shares, which had closed at $35.81 on Tuesday, fell 67 cents, or -1.9%, in premarket trading Wednesday.

The Bottom Line
We have been recommending shares of MRK since Dec.1 when the stock was trading at $36.21. The company has a 4.24% dividend yield, based on last night's closing stock price of $35.81.

Merck & Co., Inc. ( MRK ) is a "recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com



This article appears in: Investing , Stocks
More Headlines for: MERCK , MRK


More from Dividend.com







Dividend.com
Contributor:

Dividend.com

Dividends
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com